This is a prospective, multi-centre, long-term, follow-up study for participants who received GT005 in an antecedent clinical study (GT005-02 or GT005-03).~No further investigational product will be administered within this study, and participants will be invited to enter ORACLE upon their completion of the antecedent interventional study.~This study will consist of up to five study visits over a 3-year period (a total follow up period of 5-years post-GT005 administration).
The purpose of this study is to evaluate the long-term safety and durability of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.